Studies in APP/PS1 mice and AD patients treated with c-Abl inhibitors like imatinib and nilotinib diminished Aβ deposits in the brain and blood (Cancino et al., 2008; Estrada et al., 2016; Turner et al., 2020). The gene discussed is ABL1; the disease is Alzheimer disease.